Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis

JACC: Cardiovascular Imaging

Volumn 5, Issue 9, 2012, Pages 911-922

  Elkhawad, Maysoon ^a   Rudd, James H F ^a   Sarov Blat, Lea ^b   Cai, Gengqian ^b   Wells, Richard ^a   Davies, L Ceri ^c   Collier, David J ^c   Marber, Michael S ^d   Choudhury, Robin P ^e   Fayad, Zahi A ^f   Tawakol, Ahmed ^g   Gleeson, Fergus V ^e   Lepore, John J ^b   Davis, Bill ^h   Willette, Robert N ^b   Wilkinson, Ian B ^a   Sprecher, Dennis L ^b   Cheriyan, Joseph ^a,h,i  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

atherosclerosis; biomarkers; imaging; inflammation; p38 mitogen activated protein kinase inhibition; randomized controlled trial

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LOSMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; AORTA; ARTICLE; ATHEROSCLEROSIS; CARDIAC IMAGING; CAROTID ARTERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS FAT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULITIS;

AGED; ANTI-INFLAMMATORY AGENTS; AORTITIS; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CYCLOPROPANES; DOUBLE-BLIND METHOD; FEMALE; FLUORODEOXYGLUCOSE F18; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INTRA-ABDOMINAL FAT; MALE; MIDDLE AGED; ODDS RATIO; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PYRIDINES; RADIOPHARMACEUTICALS; SUBCUTANEOUS FAT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866308280     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2012.02.016     Document Type: Article

References (35)

1. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
2. T. Senokuchi, T. Matsumura, M. Sakai et al. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase mediate macrophage proliferation induced by oxidized low-density lipoprotein Atherosclerosis 176 2004 233 245
3. A.J. Muslin MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets Clin Sci (Lond) 115 2008 203 218
4. F.H. Seeger, D. Sedding, A.C. Langheinrich, J. Haendeler, A.M. Zeiher, S. Dimmeler Inhibition of the p38 MAP kinase in vivo improves number and functional activity of vasculogenic cells and reduces atherosclerotic disease progression Basic Res Cardiol 105 2010 389 397
5. R.N. Willette, M.E. Eybye, A.R. Olzinski et al. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease J Pharmacol Exp Ther 330 2009 964 970
6. J.B. Morris, A.R. Olzinski, R.E. Bernard et al. p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment Arterioscler Thromb Vasc Biol 28 2008 265 271
7. L. Sarov-Blat, J.M. Morgan, P. Fernandez et al. Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans Arterioscler Thromb Vasc Biol 30 2010 2256 2263
8. J. Cheriyan, A.J. Webb, L. Sarov-Blat et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia Circulation 123 2011 515 523
9. R. Kubota, S. Yamada, K. Kubota, K. Ishiwata, N. Tamahashi, T. Ido Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography J Nucl Med 33 1992 1972 1980
10. M. Ogawa, Y. Magata, T. Kato et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques J Nucl Med 47 2006 1845 1850
11. A. Tawakol, R.Q. Migrino, G.G. Bashian et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients J Am Coll Cardiol 48 2006 1818 1824
12. E.J. Folco, Y. Sheikine, V.Z. Rocha et al. Hypoxia but not inflammation augments glucose uptake in human macrophages implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography J Am Coll Cardiol 58 2011 603 614
13. J.H. Rudd, E.A. Warburton, T.D. Fryer et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography Circulation 105 2002 2708 2711
14. N. Tahara, H. Kai, M. Ishibashi, H. Nakaura et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography J Am Coll Cardiol 48 2006 1825 1831
15. S.J. Lee, Y.K. On, E.J. Lee, J.Y. Choi, B.T. Kim, K.H. Lee Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction J Nucl Med 49 2008 1277 1282
16. N. Tahara, H. Kai, S. Yamagishi et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome J Am Coll Cardiol 49 2007 1533 1539
17. G.A. Rosito, J.M. Massaro, U. Hoffmann et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study Circulation 117 2008 605 613
18. T. Christen, Y. Sheikine, V.Z. Rocha et al. Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging J Am Coll Cardiol Img 3 2010 843 851
19. J.H. Rudd, K.S. Myers, S. Bansilal et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations J Nucl Med 49 2008 871 878
20. J.H. Rudd, K.S. Myers, S. Bansilal et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials J Am Coll Cardiol 50 2007 892 896
21. Z.A. Fayad, V. Mani, M. Woodward et al. Rationale and design of dal-PLAQUE: A study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Am Heart J 162 2011 214 221.e2
22. M. Graebe, S.F. Pedersen, L. Hojgaard, A. Kjaer, H. Sillesen 18FDG PET and ultrasound echolucency in carotid artery plaques J Am Coll Cardiol Img 3 2010 289 295
23. S.F. Pedersen, M. Graebe, A.M. Fisker Hag, L. Hojgaard, H. Sillesen, A. Kjaer Gene expression and 18FDG uptake in atherosclerotic carotid plaques Nucl Med Commun 31 2010 423 429
24. J.L. Martin-Ventura, L.M. Blanco-Colio, A. Gomez-Hernandez et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month Stroke 36 2005 1796 1800
25. F.F. Ribeiro-Filho, A.N. Faria, S. Azjen, M.T. Zanella, S.R. Ferreira Methods of estimation of visceral fat: advantages of ultrasonography Obes Res 11 2003 1488 1494
26. Y. Sheikine, K. Akram FDG-PET imaging of atherosclerosis: do we know what we see? Atherosclerosis 211 2010 371 380
27. L.J. Menezes, C.W. Kotze, B.F. Hutton et al. Vascular inflammation imaging with 18F-FDG PET/CT: when to image? J Nucl Med 50 2009 854 857
28. J.M. Lee, F. Wiesmann, C. Shirodaria et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging Atherosclerosis 197 2008 951 958
29. S.E. Nissen, S.J. Nicholls, I. Sipahi ASTERIOD Investigators Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial J Am Med Assoc 295 2006 1556 1565
30. J.T. Deichen, O. Prante, M. Gack, K. Schmiedehausen, T. Kuwert Uptake of [18F]fluorodeoxyglucose in human monocyte-macrophages in vitro Eur J Nucl Med Mol Imaging 30 2003 267 273
31. R.J. Gropler, L.R. Peterson Adipose tissue imaging the potential and the challenge J Am Coll Cardiol Img 3 2010 852 853
32. G. Sweeney, R. Somwar, T. Ramlal, A. Volchuk, A. Ueyama, A. Klip An inhibitor of p38 mitogen-activated protein kinase prevents insulin-stimulated glucose transport but not glucose transporter translocation in 3T3-L1 adipocytes and L6 myotubes J Biol Chem 274 1999 10071 10078
33. H. Hauner, T. Petruschke, M. Russ, K. Röhrig, J. Eckel Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture Diabetologia 38 1995 764 771
34. P.W. Wilson, M. Pencina, P. Jacques, J. Selhub, R. D'Agostino Sr., C.J. O'Donnell C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study Circ Cardiovasc Qual Outcomes 1 2008 92 97
35. P.M. Ridker Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 107 2003 363 369